FujiFilm Holdings will acquire Merck & Company’s two biodrug manufacturing units, The Wall Street Journal reports, citing Nikkei. The Japanese maker of imaging equipment and digital cameras will buy wholly owned subsidiaries MSD Biologics of the U.K and Diosynth RTP of the U.S. The financial terms of the deal have not been disclosed, but it is expected to be around $490 million. The company plans to complete the deal with the U.S. drug maker, Merck, by the beginning of April.
Click here for the story from The Wall Street Journal.